Current Heart Failure Reports

, Volume 9, Issue 2, pp 117–127

Chemotherapy-Induced Cardiotoxicity

Management of Heart Failure (T Meyer, Section Editor)

DOI: 10.1007/s11897-012-0083-y

Cite this article as:
Shaikh, A.Y. & Shih, J.A. Curr Heart Fail Rep (2012) 9: 117. doi:10.1007/s11897-012-0083-y


Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of β-blockers and angiotensin-converting enzyme inhibitors in the treatment of heart failure is well proven. The role of these medications in the prevention and treatment of chemotherapy-induced cardiotoxicity is not well established.


Doxorubicin Anthracycline Trastuzumab Heart failure Cardiomyopathy Chemotherapy Management Tyrosine kinase inhibitors TKIs Cardiotoxicity Cardio-oncology 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.University of Massachusetts Memorial Medical CenterWorcesterUSA

Personalised recommendations